Home Granite Bio

Granite Bio

In operation
Series B
Novel Monoclonal Antibody Developer

Basic Information

Granite Bio is a Swiss biotechnology company. Granite Bio is developing a novel monoclonal antibody for the treatment of autoimmune and certain cancer indications.
Granite Bio AG
Basel,CantonofBasel-City,Switzerland
less than 15 people
January 01, 2020
info@granitebio.com